What's Happening?
Bausch + Lomb has announced positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, designed for treating elevated intraocular pressure in patients with open-angle glaucoma. The ELIOS procedure, which is implant-free and utilizes
excimer laser technology, demonstrated significant intraocular pressure reduction in the trial. Conducted across 20 sites in the U.S., the study involved 318 patients with mild to moderate primary open-angle glaucoma and cataracts. The trial met its co-primary effectiveness endpoints, with 76% of patients achieving at least a 20% reduction in intraocular pressure and an average decrease of 7.4 mmHg. Additionally, 82% of patients were medication-free at 23 months, and no intraoperative complications were reported. The ELIOS procedure is currently CE marked in Europe but has not yet been reviewed by the FDA for safety and efficacy in the U.S.
Why It's Important?
The positive results from the ELIOS System trial are significant as they offer a promising new treatment option for glaucoma, a leading cause of blindness. The procedure's ability to reduce intraocular pressure without the need for implants or ongoing medication could transform glaucoma management, particularly for patients who struggle with medication adherence. The success of the ELIOS System in the U.S. trial could pave the way for its approval by the FDA, potentially providing a less invasive alternative to traditional surgical methods like trabeculectomy. This development could have a substantial impact on the ophthalmic community and patients, offering a safer and more effective treatment option.
What's Next?
Bausch + Lomb plans to share the full dataset from the trial with the broader ophthalmic community and submit detailed results to a future medical meeting and a peer-reviewed journal. The company is likely to seek FDA approval for the ELIOS System, which could lead to its introduction in the U.S. market. If approved, the ELIOS System could become a preferred treatment option for glaucoma specialists, potentially influencing treatment protocols and patient outcomes. The ophthalmic community will be closely watching for further developments and regulatory decisions regarding the ELIOS System.
